Catherine Creticos

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial

Eric S. Daar, Edwin DeJesus, Peter Ruane et al. · The Lancet HIV · 2018 · 180 citations

Medicine, Infectious Diseases, Pharmacology +16

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

Jean‐Michel Molina, Kathleen Squires, Paul E. Sax et al. · The Lancet HIV · 2018 · 145 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +10

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Hans‐Jürgen Stellbrink, José Ramón Arribas, Jeffrey L. Stephens et al. · The Lancet HIV · 2019 · 143 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Mpox in people with past infection or a complete vaccination course: a global case series

Aniruddha Hazra, Jason Zucker, Elizabeth Bell et al. · The Lancet Infectious Diseases · 2023 · 141 citations · Full text

Medicine, Immunology, Infectious Diseases +9

HIV Sexual Risk Behavior Over 36 Months of Follow-Up in the World's First HIV Vaccine Efficacy Trial

Bradford N. Bartholow, Susan Buchbinder, Connie Celum et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2005 · 97 citations

Medicine, Health Behavior, Preventive Medicine +17